Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesApimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
2.36 USD -0.33 ( 12.27%)
Last update at 2026-11-11T21:00:00Z
VOLUME
60431
Market Cap
23.64M

Momentum Score

…

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.22
Low
2.68
High
52 Week Price Range
0.95
Low
4.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Apimeds Pharmaceuticals US, Inc. is a small publicly traded company that identifies as operating in the pharmaceutical sector; public disclosures and SEC filings are limited and provide few verifiable details on products, pipeline or revenue. Long-term growth would depend on successful clinical or product development, regulatory approvals and effective commercialization, and the company may benefit from any validated therapeutic assets or strategic partnerships that materialize.

Key risks include limited public information, absence of confirmed operating revenue, high financing and regulatory uncertainty, significant execution risk typical of small-cap drug developers and thin trading liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.69
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.44
ROE
-
Net Debt
0.59M
ROCE
126.09%
Diluted EPS TTM
-0.41

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.39M -0.78M -0.67M -1.03M
Net income -1.39M -0.78M -0.67M -1.03M
Selling general administrative 1.28M 0.65M 0.27M 0.53M
Ebitda -1.27M -0.74M -0.64M -1.02M
Operating income -1.28M -0.75M -0.64M -1.02M
Other operating expenses 1.28M 0.75M 0.64M 1.02M
Interest expense 0.12M 0.04M 0.03M 0.01M
Interest income 0.00M 0.01M 0.00M -
Net interest income -0.11M -0.03M -0.03M -0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.28M 0.75M 0.64M 1.02M
Total other income expense net -0.11M -0.03M -0.03M -0.01M
Net income from continuing ops -1.39M -0.78M -0.67M -1.03M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.01M 0.42M 0.01M 0.17M
Other current assets 0.01M 0.01M - 0.00M
Total liab 1.37M 0.39M 0.72M 0.41M
Total stockholder equity -1.36M 0.03M -0.71M -0.24M
Other current liab 0.77M 0.12M 0.02M -
Common stock 0.08M 0.21M 0.10M 0.10M
Capital stock 0.08M 0.08M 0.10M 0.10M
Retained earnings -4.39M -3.00M -2.22M -1.56M
Cash 0.00M 0.41M 0.01M 0.17M
Total current liabilities 1.02M 0.12M 0.32M 0.01M
Net debt 0.59M -0.14M 0.65M 0.23M
Short term debt 0.25M - 0.26M -
Short long term debt 0.25M - 0.26M -
Short long term debt total 0.60M 0.27M 0.66M 0.40M
Other stockholder equity 2.95M 2.83M 1.41M 1.22M
Total current assets 0.01M 0.42M 0.01M 0.17M
Long term debt 0.35M 0.27M 0.40M 0.40M
Accounts payable - - 0.04M 0.01M
Non current assets total 0.00M 0.00M 0.00M 0.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 0.00M 0.00M 0.00M
Net borrowings 0.25M 0.00M 0.26M 0.40M
Total cash from financing activities 0.33M 1.03M 0.28M 0.40M
Net income -1.39M -0.78M -0.67M -1.03M
Change in cash -0.41M 0.40M -0.17M -0.42M
Begin period cash flow 0.41M 0.01M 0.17M 0.59M
End period cash flow 0.00M 0.41M 0.01M 0.17M
Total cash from operating activities -0.73M -0.63M -0.45M -0.82M
Issuance of capital stock 0.00M 1.05M 0.00M -
Other cashflows from financing activities 0.08M -0.02M 0.02M -
Capital expenditures 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.54M 0.04M -0.00M 0.00M
Stock based compensation 0.00M 0.07M 0.19M 0.19M
Other non cash items 0.12M 0.04M 0.03M 0.01M
Free cash flow -0.73M -0.63M -0.45M -0.82M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
APUS
Apimeds Pharmaceuticals US, Inc.		 -0.33
12.27%		 2.36 - - - 2.90
MKKGY
Merck KGaA ADR		 0.13
0.39%		 33.80 21.25 14.93 3.10 2.14
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 169.12 24.86 15.11 3.13 1.98
TAK
Takeda Pharmaceutical Co Ltd ADR		 -
-%		 20.84 - 10.96 0.01 1.20
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16

Profile*

Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

B4-204A5, Business Centre 04, Ras al-Khaimah, United Arab Emirates

848 201 5010

https://www.mindwavedao.com

2

Name Title Year Born
Mr. Erik C. Emerson President 1971
Mr. Erick J. Frim Chief Financial Officer 1958
Dr. Christopher M. H. Kim M.D. Chief Medical Officer 1951
Dr. Vinod Menon Founder, CEO & Director 1978
Captain Sandeep Singh Yadav Chief Operating Officer NA
Mr. Amardeep Singh Chief Technology Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…